Stryker (SYK) Q2 2026 Earnings Call Transcript
Stryker (SYK) reported Q2 2026 adjusted EPS of $3.69, up 17.9% year over year, with organic net sales up 9% and adjusted gross margin at 66%. Management cited recovery from a prior cybersecurity incident and higher production. Full-year organic net sales guidance is 8.3% to 9.3%, and adjusted EPS guidance is $14.95 to $15.10.
How this was made
The 30-second read
Why it matters
The most tradable elements are the updated full-year organic net sales range (8.3% to 9.3%) and adjusted EPS range ($14.95 to $15.10), plus the margin drivers (tariff benefit, mix, cost discipline) and the explicit supply disruption risk in peripheral vascular.
Market read
Traders can update positioning based on the combination of improved margins, narrowed guidance, and quantified operational risks (backorders and cyber remediation costs).
What to watch
Investors may underweight the mix shift toward ambulatory surgery centers (hip and knee site-of-care near 20%) and the execution risk in scaling Mako robotics applications and the Encompass and Sonopet 3 launches.
Background
This is a transcript-style summary of Stryker’s Q2 2026 earnings call, covering organic sales, margins, guidance, and operational updates after a prior cybersecurity incident.
Ticker impact
Stryker reported Q2 2026 adjusted EPS of $3.69 and raised/narrowed full-year organic sales guidance to 8.3% to 9.3%.
Bias toward upside if investors trust remediation progress and production ramp, with volatility around any further supply disruption.
The call discloses specific Q2 profitability metrics (gross margin 66%, operating margin 27.4%) and updated full-year EPS ($14.95 to $15.10) alongside a concrete risk (lost sales from peripheral vascular backorder).
Market effects
Medical device peers may see read-across on orthopedic and robotics demand durability, especially around Mako installations and ambulatory site-of-care shift.
International growth commentary highlights continued strength in Australia, New Zealand, Germany, and Canada, supporting global medtech demand expectations.
Tariff benefit and cyber remediation costs are company-specific, but they can influence broader investor focus on margin resilience and operational risk management in medtech.
Counterpoint
The guidance narrowing could still mask uneven recovery, since the company explicitly cites lost sales from peripheral vascular backorders and ongoing cyber remediation costs.
Key entities
- companyStryker
Reported Q2 2026 results and updated full-year guidance, citing margin expansion and ongoing remediation/supply disruption risks.
- executiveKevin A. Lobo
CEO who discussed recovery from the cybersecurity incident and the peripheral vascular backorder impact.
- executivePreston Wells
CFO who discussed adjusted margin drivers and cyber-related costs.
